dr. abigail a. barrow chair malsi · 2017-06-05 · joe gormley, cto, iomics corp ali...

June 1, 2017

Welcome to our 10th Massachusetts Life Sciences Innovation Day!

Once again, it is our pleasure to bring together major organizations throughout the state to create a high-energy, hands-on event which includes scientific leaders and business experts to mingle with innovators, post-docs, professors, entrepreneurs, and venture capitalists. As we have been saying for the last 10 years - this is the biggest day for life sciences startups and innovation in the Com-monwealth of Massachusetts.

This year’s theme is “Inventing the Future – The Path from Invention to Innovation.” This reflects our continuing goal for the program – to support the discovery of new inventions that will have an impact on patients’ lives and to ensure that these inventions are taken out of the lab and commercialized. Our speakers and panelists, drawn from a wide variety of technology areas and with plentiful experi-ence, will consider how you can commercialize your new invention and create new start-ups, as well as provide an overview of some new emerging industry sectors. We hope you find their discussions thought provoking.

The Poster Competition includes some of the greatest and newest ideas that could impact medicine in the future. Remember to invest your “MALSI dollars” in your favorite posters – it could help the inventors raise their first round of investment! Winners will be announced during our ever popular evening reception. The reception will also be attended by many additional life sciences CEOs who will join us late afternoon to help judge the poster finalists. Do not miss the opportunity to speak with them and pitch your projects.

We are particularly grateful to our Planning Committee for their help, support and entrepreneurial spirit in organizing this event. We would also like to thank all of our sponsors, particularly Pepper Hamilton LLP and the Massachusetts Life Sciences Center, who continue to be our lead sponsors. All of our sponsors are as committed as we are to supporting the creation of new companies and we are grateful to them all.

And finally, the Planning Committee would also like to take this opportunity to remember Carolyn Green who passed away in mid-April after a very brief illness. Carolyn was Executive Director, Strategic Investments, Pfizer Worldwide R&D and previously was involved as an investor and as a founder in many life sciences startups. She had also worked in the development of technology com-mercialization activities while she was at the University of Pittsburgh. She was a great friend of life-sciences researchers and entrepreneurs, spending considerable time helping them think through how their technology could be commercialized. And finally she was an avid supporter of MALSI Day – having participated on various panels and as a judge. We will all miss her greatly.

We hope you enjoy our flagship event of life sciences in Massachusetts, jointly and actively put together by all the major organizations that are involved in starting and supporting the life sciences start-up ecosystem in the Commonwealth.

Dr. Abigail A. BarrowChair MALSIDirector, MTTC

10th AnnualMassachusetts Life Sciences Innovation Day

ii

Table of ContentsFloor Plan – Harvard Club of Boston ...............................................................................................iii

Conference Agenda .............................................................................................................................iv

Sponsors, Affiliates & Organizers ......................................................................................................7Gold Sponsors................................................................................................................................................................... 8Silver Sponsors ...............................................................................................................................................................10Conference Supporters ...............................................................................................................................................11Organizers ........................................................................................................................................................................12In association with .......................................................................................................................................................15

Speaker Biographies ........................................................................................................................... 17

MALSI Day Planning Committee ................................................................................................... 35

Poster Presenters ................................................................................................................................. 37

Innovators’ Marketplace Exhibitors ............................................................................................... 44Life Science Products and Services ........................................................................................................................44Entrepreneurship Support .........................................................................................................................................44Funding .............................................................................................................................................................................45Professional Services ....................................................................................................................................................45

Floor Plan – Harvard Club of Boston

HARVARD HALL

FOYER

PRESIDENT’SROOM

VERITASLOUNGE

VERITASROOM

BACK BAYWINE ROOM

FINISHINGKITCHEN

PLATINGKITCHEN

ELEVATORELEVATOR

BATHROOM

ENTRY

RECEPTION

HARVARDHALL

CORRIDOR

MEN’SROOM

WOMEN’SROOM

COATS

COATS

BUSSING

HARVARD CLUB OF BOSTON374 COMMONWEALTH AVE. BOSTON, MAFIRST FLOOR PLAN

COMMONWEALTHAVENUE

OFFICE

LOBBY

ELEVATORELEVATOR

FOYERHARVARD

HALL

MEN’SROOM

WOMEN’SROOM

COMMONWEALTHAVENUE

HARVARD CLUB OF BOSTON374 COMMONWEALTH AVE. BOSTON, MASECOND FLOOR PLAN

PANTRY

DBW

CORRIDOR

GARDNERROOM

AESCULAPIANROOM

MASSACHUSETTSROOM

MASSACHUSETTS FOYER

TIME SESSION

Foyer Harvard Hall

8:00 AM Registration & Breakfast

Harvard Hall

9:00 AM Welcome by Conference Chair Abigail Barrow, Director, Massachusetts Technology Transfer Center

9:10 AM Opening KeynoteGreg L. Verdine, Erving Professor of Chemistry, Harvard University and Harvard Medical School

9:40AM Plenary Panel: Recently Funded Startups

Evan Ehrenberg, Co-Founder & CEO, Clara HealthJoe Gormley, CTO, IOMICS Corp

Ali Haghighi-Mood, CEO, Sirona Medical TechnologiesSven Karlsson, President & Co-Founder, Platelet Biogenesis

Moderator:

Steve London, Partner, Pepper Hamilton LLP

Foyer Harvard Hall and President’s Room on the 1st Floor

10:30AM NETWORKING BREAK / POSTER & STARTUP SHOWCASE

Massachusetts Room Aesculapian Room

11:00 AM Looking Backward - Entrepreneurial Voyages by Prior MALSI Inventors

Panelists:

Nina Dudnick, Founder & CEO, Seeding Labs

Jeff Karp, Associate Professor, Harvard Medical School

Danny Levner, CTO & Co-founder, Emulate

Walter Ogier, CEO, Acetylon

Moderator: Shawn Foley, Of Counsel, Burns & Levinson

LLP

Proof-of-Concept Projects – CRO Partnership

CASE STUDY I:

Children’s Hospital and ARAGEN Biosciences

Brian Cain, Regional Director of East Coast Sales & Business Development, Aragen Bioscience

Carla Haslauer, Principal, Technology Development Fund, TIDO, Boston Children’s Hospital

CASE STUDY II:

3 Point Bio & CRL

Brian Hubbard, CEO, 3 Point Bio

Swati Prasad, Senior Manager, Business Development and Scientific Alliances Discovery,

Charles River Laboratories

Harvard Hall

12:15 PMWelcome by Travis McCready, President & CEO, Massachusetts Life Sciences Center

Lunch Keynote

Donald E. Ingber, Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University


1:45 PM What Does BigCo Want from NewCo?

Panelists:

Anil Achyuta, Director of Advanced Research, L’Oreal

Lily Cortese, Director, J&J Innovation Center

Kathryn McCabe, Director, Emerging Technology & Innovation, Eli Lilly

Rich Wilmot, Head of Philips HealthTech Ventures

Moderator:

Carl Berke, Partner, Partners HealthCare Innovation Fund

Monetizing the Microbiome

Panelists:

Lynn Bry, Director, Center for Metagenomics, Brigham & Womens Hospital

Jonathan Freeman, Chief Business Officer, Vedanta Bioscience, Inc.

Matthew Henn, Senior VP, Head of Drug Discovery & Bioinformatics, Seres

Jen Rice, Associate Director of Business Development, OTD, Harvard University

Moderator:

William Bonificio, VP, Shumway Capital

Foyer Harvard Hall and President’s Room on the 1st Floor

3:00PM NETWORKING BREAK / POSTER & STARTUP SHOWCASE


3:30PM Understanding Healthcare Economics and How It Will Affect Your Start-up

Panelists:

Ed Berger, Founder, Larchmont Strategic Advisors

Sheela Hegde, Partner, Health Advances

Kevin Slatkavitz, Founder & President, ThinkQuality

Moderator:

John Hallinan, Chief Business Officer, MassBio

Liquid Biopsy

Panelists:

Viktor Adalsteinsson, Broad InstituteLuba Greenwood,Vice President, Roche

DiagnosticsLong Le, Director of Technology Development,

MGH CID

Moderator: Glenn Miller, Market Sector Leader, Partners

Innovation

Harvard Hall

5:00 PM Reception / Innovators’ Marketplace

Poster Awards by Sarah Urban, Educational Events Manager, Charles River Laboratories

6 Sponsors & Organizers

10th Annual Massachusetts Life Sciences Innovation Day

Sponsors & Organizers 7

June 1, 2017Harvard Club of Boston

Sponsors, Affiliates & OrganizersGold Sponsors..........................................................................................................................................8

Massachusetts Life Sciences Center ......................................................................................................................... 8Pepper Hamilton LLP...................................................................................................................................................... 9

Silver Sponsors ..................................................................................................................................... 10Burns & Levinson LLP ...................................................................................................................................................10Charles River Laboratories ..........................................................................................................................................10MassBio .............................................................................................................................................................................11

Conference Supporters ..................................................................................................................... 12Lathrop &Gage LLP ......................................................................................................................................................12PCI Synthesis ...................................................................................................................................................................12MassGlobal Partners .....................................................................................................................................................12

Organizers .............................................................................................................................................. 13Massachusetts Technology Transfer Center .........................................................................................................13Mass Medical Angels ...................................................................................................................................................14Harvard Biotechnology Club .....................................................................................................................................14MALSI .................................................................................................................................................................................15

In association with ............................................................................................................................. 16Boston Life Science Networking ..............................................................................................................................16CreaGen Chemistry Incubator ..................................................................................................................................16CIMIT ..................................................................................................................................................................................16Draper ................................................................................................................................................................................16Harvard Alumni Entrepreneurs ................................................................................................................................16M2D2 .................................................................................................................................................................................16Mansfield Bio-Incubator..............................................................................................................................................16Mass-AWIS ........................................................................................................................................................................16Massachusetts Biomedical Initiatives ....................................................................................................................16MassChallenge ...............................................................................................................................................................16MassMedic .......................................................................................................................................................................16Massachusetts Technology Collaborative ...........................................................................................................16Massachusetts Technology Leadership Council .................................................................................................16NEHEN ...............................................................................................................................................................................16North Shore InnoVentures ........................................................................................................................................16OPEN .................................................................................................................................................................................16Safety Partners, Inc. ......................................................................................................................................................16The Capital Network ....................................................................................................................................................16TiE ........................................................................................................................................................................................16VentureWell ....................................................................................................................................................................16WEST ..................................................................................................................................................................................16University of Massachusetts ......................................................................................................................................16



Gold Sponsor

The Massachusetts Life Sciences Center is promoting innovation and growth across the Commonwealth. Through infrastructure investments, workforce

development programs, tax incentives and early-stage funding, we are strengthening

Massachusetts’ position as the global leader in life sciences.

masslifesciences.com



Gold Sponsor

A HOLISTIC APPROACH

For more than 50 years, we have helped clients across the health sciences spectrum — from discovery of new therapies to delivery of

patient care. With 110 lawyers devoted to helping health sciences

clients succeed, we understand the impact our advice and counsel in

one area will have on all aspects of your business.

Berwyn Boston DetroitHarrisburg Los AngelesNew York Orange CountyPhiladelphiaPittsburghPrincetonSilicon ValleyWashingtonWilmington

pepper.law

THE POWER OF

INTEGRATION



Silver Sponsors

We are proud to support the 2017 Massachusetts Life Sciences Innovation Day.

amazing discoveries

VIVARIUM SPACE FOR LEASE.CONCIERGE INCLUDED.

The Charles River Accelerator and Development Lab - CRADL™ is our new option providing turnkey vivarium rental space in Cambridge MA, right in the heart of Kendall Square. This secure, modern laboratory will allow you to invest in your research projects instead of infrastructure, without compromising the quality of your workspace or equipment. Managed by our skilled technicians, your animals receive unparalleled care in compliant facilities, where you’ll also benefit from access to Charles River’s complete portfolio of integrated drug discovery resources. Learn more at www.criver.com.

www.criver.com.



Silver Sponsor

300 Technology Square, Eighth FloorCambridge, MA 02139

(617) 674-5100www.MassBio.org

The Massachusetts Biotechnology Council is an association of more than 700biotechnology companies, universities, academic institutions and other

organizations dedicated to advancing cutting-edge research. We advance

Massachusetts’ leadership in the life sciences to grow the industry, add value to the healthcare system

and improve patient lives.

Networking & Professional DevelopmentWe bring members together to discuss relevant business and scientific issues and share their experiences through members-only Forums, training and professional development, and networking events.

Access to Capital & Fostering InnovationWith our Innovation Services arm, MassBio is focused on matching our member companies with the resources they need to move cutting-edge therapies from the bench to the bedside. Programs include Pharma Days business development events and the entrepreneur mentoring program, MassCONNECT.

Purchasing PowerBy aggregating the purchasing power of the member companies within MassBio, our Purchasing Consortium allows members to access savings in key cost centers, including laboratory supplies, prescription safety eyewear, footwear, uniform and facility services, equipment maintenance, hazardous and biomedical waste removal, packaged and bulk gases, office supplies and furniture, technology hardware and services, travel management, auto insurance, domestic and international shipping, and scientific journals and subscriptions.

Public Policy & AdvocacyAt MassBio, we work to educate policy makers and the public about the specific needs of our companies as they push the boundaries of science to improve our lives. We fight for public policy initiatives and tax incentives in Massachusetts that will enable biotechnology companies to do their best work, while also maintaining an active presence in Washington to help guide federal legislation.

Economic Development & Industry DataMassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State.

MassBio Signature EventsWe encourage learning and connections among stakeholders with events like our Policy Leadership Breakfast, the MassBio Annual Meeting, Job Trends Conference, the CRO/CMO Symposium and the Patient Advocacy Summit.

facebook.com/massbio linkd.in/massbio @massbio youtube.com/massbio

REGISTER NOW!6th International Cancer Cluster Showcase – BIO 2017

Monday, June 19th, 2017, 11:30 a.m. – 4:30 p.m.; San Diego Convention Center, Upper level 26 AB + 27AB

Sign up here to meet 24 oncology companies and projects from Massachusetts, Quebec, Philadelphia, the SF Bay Area, Oslo, UK Golden Triangle, Catalonia, the Paris Region and Wallonia.

Please find the program and presenting companies at www.internationalcancercluster.org

The event is kindly sponsored by:

Poster Partner:



Conference Supporters

www.massglobalpartners.com

9 Opportunity Way | Newburyport, MA 01950 | Tel: (978) 462-555588 Jackson Road | Devens, MA 01434 | Tel. (978) 772-2111

pcisynthesis.com

At PCI, our experienced and accomplished R&D team of more than 40 professionals is ready to execute even the most challenging development projects. With deep experience in small

molecule development, manufacturing and project management for new candidates we know how to navigate the complexities of pharmaceutical R&D.

VISIT PCISYNTHESIS.COM TO LEARN MORE ABOUT HOW WE CAN HELP YOU.

Together. Moving Ideas

Forward.



Organizer

The Massachusetts Technology Transfer Center is funded by the Commonwealth of Massachusetts. Its goal is to support technology transfer activities from public and private research institutions to companies in Mas-sachusetts. To achieve this goal, the Center works with technology transfer offices at Massachusetts research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth.

_______________________________________________________________________________

The Center: • facilitates and accelerates technology transfer between research institutions and Massachusetts

companies;• promotes collaboration between research institutions and the Commonwealth’s technology in-

dustry; • assists in the growth of Massachusetts companies, including startups, by enhancing technologi-

cal leadership; and• supports regional and statewide economic development priorities.

_______________________________________________________________________________

The Center supports the commercialization of research technologies through a variety of programs:

The Center provides mentoring to researchers who believe they have a technology that could serve as the basis of a new company. The process includes the development of a business presentation for an expert board of external reviewers.

Commercialization and Entrepreneurial Education seminars and workshops enable researchers to understand the process of commercializing technologies.

Expert technology reviews provide opportunities for Massachusetts research institutes to have external industry experts evaluate technologies and give advice regarding their commercial potential.

Technology Forums allow investors and potential corporate partners to meet with companies formed around technologies developed in Massachusetts research institutes.

www.MTTC.org

www.MassTechPortal.org

[email protected]

@MassTTC



Organizers



We are motivated to leverage what is truly unique about MA

“If I stand in the middle of Mass Ave Bridge, and walk 1 mile in either direction, I have everything I need to start a billion dollar life sciences company”

The Massachusetts Life Sciences Start-up Initiative (MALSI) is a collaborative group of public and private entities that work with emerging biotech and biomed companies. The prime aim of MALSI is to ensure that every life sciences entrepreneur or researcher who has a commercializable idea has easy and rapid access to the vast network of organizations and individuals who can help them realize their dreams. The Massachusetts Technology Transfer Center, Mass MEDIC, TiE Boston, and MassBio have partnered to present the Massachusetts Life Sciences Innovation Day.

In case you have any questions, please contact

Massachusetts Technology Transfer Center at [email protected]

Please join our MALSI Group on LinkedIn.com



In association with


Biographies 17

Speaker BiographiesAnil Achyuta .......................................................................................................................................... 18Viktor Adalsteinsson ........................................................................................................................... 18Edward Berger ...................................................................................................................................... 19Carl Berke ................................................................................................................................................ 19William Bonificio .................................................................................................................................. 19Lynn Bry ................................................................................................................................................. 20Brian Cain ............................................................................................................................................... 20Lily Cortese ............................................................................................................................................ 21Nina Dudnik ........................................................................................................................................... 21Evan Ehrenberg .................................................................................................................................... 21Shawn Foley .......................................................................................................................................... 22Jonathan Freeman .............................................................................................................................. 22Joseph Gormley ................................................................................................................................... 23Luba Greenwood ................................................................................................................................. 23Ali Haghighi-Mood .............................................................................................................................. 24John Hallinan ....................................................................................................................................... 24Carla Haslauer ....................................................................................................................................... 25Sheela Hegde ........................................................................................................................................ 25Matthew Henn ...................................................................................................................................... 25Brian Hubbard ...................................................................................................................................... 26Donald E. Ingber .................................................................................................................................. 26Sven Karlsson ........................................................................................................................................ 27Jeff Karp .................................................................................................................................................. 27Long Phi Le ............................................................................................................................................ 28Danny Levner ........................................................................................................................................ 28Steve London ....................................................................................................................................... 29Kathryn (Katy) McCabe ...................................................................................................................... 29Travis A. McCready .............................................................................................................................. 29Glenn A. Miller ...................................................................................................................................... 30Walter Ogier ........................................................................................................................................... 30Swati Prasad .......................................................................................................................................... 31Jen Rice ................................................................................................................................................... 31Kevin J. Slatkavitz ................................................................................................................................. 31Greg L. Verdine ..................................................................................................................................... 32Rich Wilmot ........................................................................................................................................... 33


18 Biographies

Speaker Biographies

Anil AchyutaDirector of Advanced Research, L’Oreal

Anil Achyuta is an impact-driven professional with expertise at the interface of engineering, biology, and busi-ness. Anil is currently the Director of Advanced Research at L’Oreal, where he looks for disruptive start-ups in the beauty, materials science, dermatology, and medical aesthetics space. Anil also has collaborations with academics, dermatologists, and key opinion leaders who are changing the landscape of global beauty arena from the Boston area.

Previously, Anil advised GlaxoSmithKline’s (GSK) Bioelectronics R&D group and their Venture Arm - Action Potential Ventures (APVC) as their Associate Director. With the R&D group, Anil helped identify disease targets and key opinion leaders to validate efficacy of innovative devices in pre-clinical animal models and invested in ~$3M in ongoing proof-of-concept projects. On the Venture side, Anil managed deal flow, per-formed early-stage screens, technology analysis, and due diligences for APVC, which helped APVC’s Part-ners successfully launch 1 start-up and shape future investments.

Anil also created, led, and launched GSK’s $1M Innovation Challenge, an open global competition that aims at creating a wireless implantable platform device for mapping disease-related neural circuits in the periph-eral nervous system. Anil presented the competitive landscape, strategy, and the mechanics of this Innova-tion Challenge to GSK’s executives to get a unanimous buy-in. The Innovation Challenge also catalyzed strategic collaborations between GSK, US Government agencies, and Fortune 500 companies and was designed to closely complement President Obama’s BRAIN Initiative (NIH SPARC $250M investment, and DARPA ElectRx $79M investment).

Anil previously worked at Draper Laboratory as an R&D Leader and Business Development Executive man-aging over $5M projects spanning lab-on-a-chip, tissue engineering, and implantable devices.

Prior to GSK and Draper, Anil spent over 2 years at an MIT start-up called GVD Corporation in Cambridge, MA. At GVD, Anil invented a new silicone polymer product line, designed manufacturing processes that would increase the efficiency of this process to reduce COGS and this product (Exilis) is now in sales.

Anil maintains an active involvement with the entrepreneurial ecosystem in the Boston area. Through L’Oreal, Anil works actively with MassChallenge to identify and mentor early-stage start-ups.

Viktor AdalsteinssonGroup Leader, Broad Institute

Viktor Adalsteinsson is a Group Leader at the Broad Institute of MIT and Harvard, where he is leading the Blood Biopsy Team, a multi-institutional collaboration to profile cancer genomes directly from blood samples. The Blood Biopsy Team includes scientists, engineers, oncologists, and computational biologists spanning his lab and other labs at Broad, MIT, Dana-Farber, MGH, and beyond. The goal of their research is to iden-tify mechanisms of response and resistance to therapy, enable routine monitoring of patients with cancer, and someday, provide a mechanism for early detection of cancer. Please see WBUR for recent coverage of their work. Adalsteinsson holds a PhD in Chemical Engineering from MIT (laboratory of J. Christopher Love) where he developed novel approaches for functional and genomic profiling of single cells in cancer. Adalsteinsson joined the Broad Institute as a Research Affiliate during his doctoral studies at MIT and was subsequently tapped to lead the Blood Biopsy Team.


Biographies 19

Edward BergerPolicy, Reimbursement and Strategy Counsel for the Life Sciences

A senior healthcare executive with more than 30 years of experience in life science and medical technology reimbursement analysis, planning and advocacy, Ed Berger founded Larchmont Strategic Advisors in 2005 to help early stage companies deal effectively with the strategic challenges and opportunities posed by the rapidly evolving healthcare regulatory and policy environment. Building upon the knowledge and experience gained as a member of the management teams of such companies as Fresenius Medical Care, Thermo Cardiosystems, and ABIOMED, Dr. Berger has provided reimbursement analysis and strategy development consultation to a variety of clients developing new technologies in fields including mechanical circulatory support, orthopedics, neural monitoring and neuromodulation, gastrointestinal surgery, severe pulmonary dysfunction, nuclear medicine, diagnostic imaging, clinical laboratory testing, and personalized medicine. In addition to reimbursement-related services and public policy analysis and advocacy, his areas of expertise include media relations, investor relations, research ethics and patient protection, and corporate compliance programs.

Carl BerkePartner, Partners HealthCare Innovation Fund

Carl is a Partner at Partners HealthCare Innovation Fund in Boston, investing in new biomedical technologies emerging from Massachusetts General Hospital and Brigham & Womens Hospital. His career has spanned over 25 years in the practice and management of innovation to bring new technologies from lab to market.

As a bench scientist and R&D director, he worked at Polaroid Corporation and Hygeia Sciences in the de-velopment of photographic and clinical products – he is an inventor on 6 US patents. He served as a Partner at Integral/Analysis Group, a management consultancy focused on innovation and growth strategy. He has been an active private equity investor as a member of Angel Healthcare Investors LLC and is a founding director of Mass Medical Angels LLC. He has served on the boards of Quosa [literature management soft-ware], Kasalis [robotics], Annovation [novel anesthetics], Combinent [drug delivery], Sebacia [acne treat-ment], Infobionic [cardiac monitoring], QPID Health [bioinformatics], LifeImage [diagnostic image sharing], Syntimmune [autoimmune therapy] and the Sudanese Education Fund [philanthropy].

Carl holds an AB degree from Cornell University and received his PhD in Organic Chemistry from the Univer-sity of California at Berkeley. He also holds an appointment as Lecturer in the Biomedical Enterprise Program in the Harvard-MIT Division of Health Sciences and Technology.

William BonificioVP, Shumway Capital

William Bonificio, Ph. D. is a VP at Shumway Capital where he focuses on biotech investing and company creation. He holds a BS in materials science and engineering from Cornell University and a PhD in applied physics from Harvard University. Prior to his role at Shumway he was an associate at RA Capital Manage-ment, a crossover fund that invests in healthcare and life science companies. At RA he was a domain expert on urology, aesthetics, dermatology, and microbiome science. During his time there, he helped conceive of and create a portfolio company that raised a series A financing. Before that, he was an Entrepreneurship


20 Biographies

Fellow at Flagship Ventures, a venture capital fund focusing on venture creation. At Flagship he conceived of the company now known as VL41, another series A capitalized company. Prior to that, he was the first employee of Kaleido Biosciences, a clinical stage microbiome company. He also co-founded and operates the American Microbiome Institute, a nonprofit organization devoted to microbiome research and education.

Lynn Bry Director of the Center for Metagenomics, Brigham & Womens Hospital

Dr. Bry is a Co-Investigator at the Partners Biobank, which is consenting patients at two Partners Healthcare institutions, BWH and MGH, to enable studies furthering biomarker development and validation for person-alized medicine. She is an Assistant Professor of Pathology at Harvard Medical School and an Associate Medical Director in the Department of Pathology at BWH. She also directs the Crimson Project that has developed IT tools and infrastructure to support high-throughput and sample collection that occurs in a cost-effective and IRB-compliant manner. Working with i2b2 (Informatics for Integrating Biology with the Bedside), an NIH-funded National Center for Biomedical Computing, Crimson has enabled many large-scale genomic studies by supplying tens of thousands of phenotyped samples at a fraction of the costs commonly incurred to obtain adequate materials.

Dr. Bry is a Board-certified pathologist and specializes in clinical laboratory testing in molecular diagnostics, microbiology and immunology. She routinely works with research groups to develop novel markers into diag-nostic assays that can be run on platforms used in clinical laboratories. She also maintains an NIH-funded research laboratory, studying host-pathogen-commensal interactions in the gut.

Brian CainRegional Director of East Coast Sales & Business Development, Aragen Bioscience

Brian Cain is the Regional Director of East Coast Sales & Business Development for Aragen Bioscience (a GVK BIO Company) and is currently responsible for overseeing business development-related activities, as well as, sales & client relationship activities on the East Coast.

Before joining Aragen Bioscience, Brian spent a year & 9 months at ACD (Advanced Cell Diagnostics) devel-oping business relationships & creating new opportunities for selling Products & Services related to ACD’s RNAscope technology platform in the New England territory. Before joining ACD, Brian spent five and a half years at Blue Sky BioServices in Worcester, MA where he was primarily responsible for managing BioSer-vices customer relationships & developing sales strategies for new services & products. Just prior to join-ing Blue Sky, Brian also spent six years at the Novartis Institutes for BioMedical Research, Inc. (NIBRI) in Cambridge, MA, working in a variety of roles within the Novartis Oncology Department which included assay development, focused library screening and global operations. Eventually Brian joined Novartis’ Strategic External Resourcing group where he was responsible for global biology outsourcing. Prior to that, he spent two years as an Assay Development scientist at Arradial, Inc. where he oversaw the development, validation & miniaturization of various kinase & phosphatase assays on a novel liquid-handling platform.

Brian earned a Ph.D. in Pharmacology & Experimental Therapeutics from the Tufts University School of Medicine where he studied the processing of neuronal precursor proteins in the brain, as well as, the conver-tases that cleaved those proteins into smaller bioactive peptides.


Biographies 21

Lily CorteseDirector, Transactions & Business Analytics, J&J Innovation Center

Lily is responsible for developing and executing transactions with our diverse industry partners, including biotech companies, venture capital, non-profit organizations, governments, and academic institutions region-ally to access innovation across J&J’s areas of interest - our pharmaceutical Therapeutic Areas, Consumer and Medical Device Businesses.

She manages all aspects of the deal process, developing value-creating deal structures, leading term sheet & contract negotiations and driving the business case development & approval process. Lily also provides business and commercial analytics capabilities to the Boston IC team.

Previously, Lily held the position of Director, Business Operations and Project Management for three and a half years at the J&J Innovation Center in London and was a founding member of the team there. Prior to joining J&J she held various roles in Business Development in both the US and UK at Huntingdon Life Sci-ences, now Envigo.

Lily holds an MBA from the University of Cambridge, Judge Business School and a BA in psychology from William Paterson University.

Nina DudnikFounder, Seeding Labs

Dr. Nina Dudnik is on a mission to ensure that talented scientists across the world have the tools, training and network to pursue life-changing science. Trained as a molecular biologist with a PhD from Harvard Univer-sity, Dr. Dudnik has worked in research labs in the US, Africa and the Middle East. As the founder of Seeding Labs, she has engaged over 100 private sector partners to provide the equivalent of more than $15 million in laboratory equipment and scientific training to scientists at 47 universities in 27 countries. Through strategic partnerships, Seeding Labs has provided employee engagement opportunities and new CSR and access to medicines initiatives for the private sector, while providing scientists around the world resources they have used to identify novel drug molecules, develop and patent agricultural technologies, train tens of thousands of students and improve the financial sustainability of their research programs.

Dr. Dudnik has received numerous awards for this work including the 2014 John F. Kennedy New Frontier Award and Scientific American’s 100 Most Influential People in Biotech 2015. Her writing and the work of Seeding Labs have been featured in a range of publications including the Wall Street Journal, National Public Radio, The Times of India and The Kenyan Standard.

Evan EhrenbergCEO, Clara

Evan started college at the age of 11, graduating from UC Berkeley with a bachelor’s degree in Cognitive Science with an emphasis in computational modeling. He was MIT’s youngest ever Ph.D. student in the de-partment of Brain and Cognitive Sciences, and is now graduating with his doctoral degree in computational neuroscience. For the last four years of his Ph.D., Evan collaborated with his co-founder Sol Chen on re-search topics ranging from computer vision to experimental neuroscience. Previously, Evan did an internship at Palantir as a forward deployed engineer and product manager.


22 Biographies

Shawn FoleyOf Counsel, Burns & Levinson LLP

With more than 30 years of experience in the field, Shawn brings refined legal and advocacy skills and tech-nical versatility. His approach to patent procurement is practical, cost effective, distinctly businessoriented and personable.

Prior to joining Burns & Levinson, Shawn played an integral role in developing his previous firm’s practice in life sciences and pharmaceuticals. A wide spectrum of clients with diverse technologies and business needs have sought his counsel, including major pharmaceutical and personal care companies, medium-sized brand and generic drug companies, start-ups, universities, and entrepreneurs, both in the U.S. and abroad.

Shawn began his career as an examiner with the U.S. Patent Office, where he reviewed patent applications during the emergence of the biotechnology field. After an initial 2-year stint with a leading Southeastern IP firm, he gained valuable corporate experience as counsel for Ciba-Geigy. At Ciba, Shawn was co-in house counsel for its agricultural biotechnology research division (now Syngenta Seeds), where he worked on a daily basis with management and scientists to gain patent protection for transgenic crop seed and to bring these first generation products to market. He also collaborated with colleagues in Switzerland and prosecut-ed patent applications directed to pharmaceuticals. Thus, Shawn has experienced many different aspects of the patent system.

Shawn has particularly enjoyed creating commercially valuable patent estates for a variety of clients. Patent estates that he has created have facilitated many licenses and outright acquisitions (e.g., by big pharma). He also has extensive experience in guiding clients and their products through the maze of third party patents. He prides himself in a communication style that is simple and direct. He is equally experienced and comfort-able in making formal presentations to Boards of Directors as he is in dealing with in-house counsel and scientists. Although he has been successful in patent appeals and post-grant matters including European oppositions, Shawn’s familiarity with the inner workings of the Patent Office and his approach to prosecuting patents has enabled him to avoid resort to appeal except in rare situations.

Over the course of his years of practicing law, Shawn has become versatile in a wide spectrum of technolo-gies. He has handled patent work involving chimeric proteins, monoclonal antibodies (including antibody drug conjugates), industrial enzymes, therapeutic and diagnostic nucleic acids, small molecules and new chemical entities, drug delivery systems (including 505(b) (2) applications), molecular diagnostics, personal care compositions and cosmetics, transgenic plants (including crop plants and use of the plants for produc-tion of protein), crop science, dental care and caries detection, and medical devices.

Jonathan FreemanChief Business Officer, Vedanta

Jonathan Freeman is Vedanta’s Chief Business Officer. An industry veteran, Jonathan joined Vedanta follow-ing a career spanning two decades in leading roles within Merck KGaA, Baxter and Serono. Within Merck, Jonathan served as Senior Vice President, Head of Strategy Development and Portfolio Management, over-seeing asset valuation, capital allocation, and strategy development guiding investment and corporate shifts resulting in, amongst other things, the launch of Bavencio in collaboration with Pfizer. Prior to Merck, Jona-than was Director of European M&A for Baxter, where he defined and executed external growth strategy, established commercial and manufacturing joint ventures, constructed, financed, and executed strategic business models and alliances working alongside multinational investment groups such as TPG and Gold-man Sachs. During his time with Serono, Jonathan was Director of Corporate and Business Development,


Biographies 23

leading licensing, alliance management, the management of private equity relationships, and participating broadly in Corporate M&A. Jonathan was a former Vice President of the Swiss Pharma Licensing Group (now SwissHLG), representative to the International Pharma Society, a faculty member of the European Centre for Pharmaceutical Medicine (ECPM), and an Editor of the Business Development & Licensing Jour-nal. Jonathan holds a First Class Honours BA in Biochemistry and an MA from Cambridge University, a Ph.D. in Molecular Pharmacology from the Imperial Cancer Research Fund (now CRUK) at the Edinburgh University Medical School, and an MBA from Geneva and Webster, St Louis Universities. Prior to entering the industry, Jonathan held assistant professor and post-doctoral positions in cancer research, gene therapy and virology in several leading academic settings including the Swiss Institute for Cancer Research (ISREC) and the Geneva Medical School (CMU) obtaining funding from the European Molecular Biology Laboratory (EMBL) and the Royal Society of London.

Joseph GormleyCTO, IOMICS Corporation

Prior to launching IOMICS, J. Gormley was an industry consultant with twenty years experience developing software for both research and clinical care. His software tools and platforms have been deployed across multiple disciplines including in silico biology, systems toxicology, neuroscience, cancer research, and emer-gency care. He is a past recipient of a JAF Innovation Grant to explore commercialization of Computational Systems Biology, has presented original engineering work on cancer patient stratification to the IBM Watson Application Team, and has been an invited speaker in QSAR/QSPR to Harvard University’s Center for In-tegrated Mesoscale Architectures. His primary interests include the use of machine learning and multiscale biochemical data in the development of feature rich software tools for rational chemical design and auto-mated identification of computable phenotypes in precision medicine. He is the lead architect on the FUSION Analytics Platform, a cloud-based software system for predictive analytics and rapid prototyping of advanced decision models for the biochemical and health sciences. He obtained a B.Sc in Computer Science from University of Maryland in 1985 and an ALM in Biology from Harvard University in 2001.

Luba GreenwoodVice President, Head of Roche Diagnostics Partnering Hub

Luba Greenwood is a Vice President of Global Mergers & Acquisitions and Business Development at F. Hoffmann-La Roche, Diagnostics. She is also heading the Roche Diagnostics Partnering Hub for the East Coast. She brings over pharmaceutical and biotechnology industry experience and expertise in building and advising innovative technology companies and providing strategic counsel to global corporations. Her career has spanned leadership roles in venture capital, business development, M&A, law, consulting, and opera-tions. Luba has recently served as a Venture Partner at Colt Ventures, and led Business Development and Strategy at a Flagship VenturesLabs company. Prior to that, Luba served as a Senior Mergers & Acquisitions Counsel at Pfizer Inc. Luba began her career practicing law at a leading national law firm, Wilmer Cutler Pickering Hale and Dorr, where she represented large multinational corporations, start-ups, and private eq-uity and venture capital funds in biotechnology, high technology, energy, and finance industries in securities, intellectual property, regulatory, and litigation matters.


24 Biographies

Luba is a professor at Boston University School of Management where she teaches Business Law, and Boston University Law School where she teaches a course on the Life Sciences. Luba serves on the board of the Longwood Symphony Orchestra, is a Co-chair of MassBio’s Entrepreneur’s University, mentor for the MIT 100K Entrepreneurship Competition, a judge for MassChallenge and the Young Entrepreneurs Initia-tive, and on a Steering Committee of the Boston Bar Association. In 2014, she received the Science Club for Girls Catalyst Award for her commitment to fostering women talent and advocating for women in science and technology.

Ali Haghighi-MoodPresident & CEO, Sirona Medical Technologies Inc.

Ali is the president and CEO of Sirona Medical Technologies, an early stage device company developing a mapping and ablation catheter for the treatment of cardiac arrhythmias. Ali has over 20 years of technical and operational experience in medical device space, including research & development, operations and general management.

Prior to Sirona Medical Technologies, Ali was the President and CEO of Cambridge Heart, a cardiac diag-nostics company and developer of the first non-invasive technology for the assessment of risk for sudden cardiac arrest approved by FDA. He holds a BS and MS degree in Electrical Engineering from University of Tehran and a PhD degree in Biomedical Engineering from the University of Sussex, UK. He also holds an appointment as Lecturer in the Institute for Medical Engineering & Science at Massachusetts Institute of Technology.

John Hallinan Chief Business Officer, MassBio

John Hallinan joined MassBio in 2012 as the Chief Business Officer and oversees the MassBio Innovation Services programs.

John’s fiscal experience in the life sciences and software industries reflect positions of increasing responsi-bility across a broad range of strategic and operational disciplines. His background encompasses venture financings, corporate development, technology licensing, and mergers and acquisitions.

Prior to MassBio, John was the Chief Financial Officer at Cytel, a leader in the design and implementation of adaptive clinical trials, and he had been active with MassBio—serving on the Economic Development Advi-sory Group and as co-chair of the Finance Committee & Entrepreneur’s University.

Before joining Cytel, John served as CFO at Signet Laboratories, a leading supplier of diagnostic assays to the pharmaceutical and biotech industries. Prior to Signet, John was interim CFO at Cambium Learning, a private equity-backed publishing company that completed two acquisitions during his tenure. John was the Chief Financial Officer of AnVil, Inc. a venture-funded silico drug discovery company, where he led the com-pany’s healthcare market business development efforts. At CambridgeSoft Corporation, John rose to CFO of that leading pharma/bio applications and enterprise solutions supplier. As Animation Technologies’ CFO, he guided the company’s first and second rounds of venture funding.

John currently sits on the Advisory Board of MTTC (the MA Technology Transfer Center).

John holds a BBA from St. Bonaventure University and is a certified public accountant. He lives with his wife Denise in Marlborough, MA.


Biographies 25

Carla HaslauerPrincipal, Technology Development Fund, Boston Children’s Hospital

Carla joined Technology and Innovation Development Office of Boston Children’s Hospital in 2014. As Prin-cipal, Technology Development Fund (TDF), Carla coordinates the TDF funding cycles and proposal evalu-ations, and project manages funded projects and external collaborations. Prior to joining TIDO, Carla was a postdoctoral scientist in the Orthopaedics Research Department at BCH. She was the recipient of an NIH F32 NRSA fellowship to support her postdoctoral research, as well as an NSF GRFP recipient for her graduate research. Carla received her Bachelor of Science in Biological and Agricultural Engineering from Louisiana State University in Baton Rouge, LA. She earned a PhD in Biomedical Engineering from the Joint Department of Biomedical Engineering at North Carolina State University and the University of North Caro-lina at Chapel Hill. Carla has authored and co-authored 16 peer-reviewed publications in the fields of tissue engineering and wound repair.

Sheela HegdePartner, Health Advances

Sheela Hegde has 15 years of experience in advising senior executive teams on corporate strategy. Sheela co-leads Health Advances’ Biopharma Practice, helping companies maximize the value of their assets and build winning market positions. Sheela brings a cross-sector lens to providing strategic advice to her clients, which include the leading pharmaceutical and biotechnology companies as well as financial investors.

Experienced in multiple therapeutic areas, Sheela has particular expertise in metabolic, CNS, and autoim-mune fields. At Health Advances, Sheela heads the Metabolics and Drug Delivery sub-practices.

Sheela joined Health Advances in 2005 with a background in corporate strategy and health care provider operations. Prior to Health Advances, Sheela worked at The Advisory Board where she managed client re-lationships and led research teams in areas related to hospital care delivery and new payment models. She also previously worked at Novartis Pharmaceuticals in the Cardiovascular Business Franchise and with the Japan affiliate.

Sheela earned a BA in human biology with university distinction and Phi Beta Kappa from Stanford Univerity, and an MBA from Harvard University

Matthew HennSenior VP, Head of Drug Discovery & Bioinformatics, Seres

Matthew Henn is the Senior Vice President and Head of Drug Discovery & Bioinformatics of Seres. He has more than 16 years of combined research experience in microbial ecology, genomics, and bioinformatics that spans both environmental and infectious disease applications. Dr. Henn’s research has focused on the development, implementation, and application of genomic technologies in the area of microbial populations and their metabolic functions. Prior to joining Seres, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard.

He has authored over 60 peer-reviewed publications in microbiology and bioinformatics, and has led multiple large-scale international genomic projects. He has served as a consultant for the WHO’s Grand Challenges


26 Biographies

in Genomics for Public Health in Developing Countries, as a scientific advisor for the National Institutes of Health’s Viral Pathogen Bioinformatics Resource Center, and as an ad-hoc reviewer and editor of many peer-reviewed journals. Dr. Henn earned his Ph.D. in ecosystem sciences from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as a NSF Postdoctoral Fellow in microbiology at Duke University.

Brian HubbardCEO, 3 Point Bio

Brian Hubbard is the CEO of 3 Point Bio, a biotech and consulting company in the life sciences.

Hubbard brings extensive knowledge of drug discovery and development. Prior to 3 Point Bio, Brian led drug discovery efforts at the Broad Institute. Before the Broad, he was Senior Director of Cardiovascular Diseases at Merck, where he was responsible for strategy and execution of research and early development. His focus was primarily atherosclerosis research. While at Merck, Hubbard was also part of a core team that developed a strategic plan for restructuring basic research in the pharmaceutical industry.

Prior to his work at Merck, Hubbard was Director of Cardiovascular and Metabolism Research at Novartis Institutes for Biomedical Research and did research into metabolic diseases and obesity at Millennium Phar-maceuticals.

Hubbard received his B.S. in chemistry from The College of William and Mary and a Ph.D. in chemistry from the University of Illinois Champaign-Urbana. He did postdoctoral research in biochemistry and antibiotics at Harvard Medical School.

Donald E. IngberFounding Director, Wyss Institute for Biologically Inspired Engineering at Harvard University

Donald E. Ingber, M.D., Ph.D., is the Founding Director of the Wyss Institute for Biologically Inspired Engi-neering at Harvard University, the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children’s Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences. He received his B.A., M.A., M.Phil., M.D. and Ph.D. from Yale University.

Ingber is a pioneer in the field of biologically inspired engineering, and at the Wyss Institute, he currently leads a multifaceted effort to develop breakthrough bioinspired technologies to advance healthcare and to improve sustainability. His work has led to major advances in mechanobiology, tumor angiogenesis, tissue engineering, systems biology, nanobiotechnology and translational medicine. Through his work, Ingber also has helped to break down boundaries between science, art and design.

Ingber has authored more than 425 publications and 150 patents, founded 5 companies, and been a guest speaker at more than 475 events internationally. He is a member of the National Academy of Medicine, Na-tional Academy of Inventors, American Institute for Medical and Biological Engineering, and the American Academy of Arts and Sciences. He was named one of the Top 20 Translational Researchers world-wide in 2012 (Nature Biotechnology), a Leading Global Thinker of 2015 (Foreign Policy magazine), and has received numerous other honors in a broad range of disciplines, including the Robert A. Pritzker Award and the Shu Chien Award (Biomedical Engineering Society), the Rous Whipple Award (American Society for Investigative


Biographies 27

Pathology), the Lifetime Achievement Award (Society of In Vitro Biology), the Leading Edge Award (Society of Toxicology), Founders Award (Biophysical Society) and the Department of Defense Breast Cancer Innova-tor Award.

Some of Ingber’s most recently developed technologies include an anticoagulant surface coating for medical devices that replaces the need for dangerous blood-thinning drugs; a dialysis-like sepsis therapeutic device that clears blood of pathogens and inflammatory toxins; a shear stress-activated nanotherapeutic that tar-gets clot-busting drugs to sites of vascular occlusion; and Human Organs-on-Chips created with microchip manufacturing methods and lined by living human cells, which are being used to replace animal testing as a more accurate and affordable in vitro platform for drug development and personalized medicine. In 2015, Ingber’s Organs-on-Chips technology was named Design of the Year by the London Design Museum and was also acquired by the Museum of Modern Art (MoMA) in New York City for its permanent design collec-tion. His Organs-on-Chips were also named one of the Top 10 Emerging Technologies of 2016 by the World Economic Forum.

Sven KarlssonPresident & Co-Founder, Platelet Biogenesis

Sven is the President and Co-Founder of Platelet BioGenesis, a venture-backed biotech startup that is commercializing the production of human platelets. He has a decade of experience working across venture capital, business development, and finance. Prior to founding Platelet BioGenesis, he worked in Mergers & Acquisitions at J.P. Morgan, as an Analyst at a hedge fund, and as a Senior Manager of Investments at a clean energy venture fund. Sven received a B.S. in Operations Research Industrial Engineering from Cornell University and an MBA with Distinction from New York University’s Stern School of Business.

Jeff KarpAssociate Professor, Brigham and Women’s Hospital & Harvard Medical School Dr. Jeff Karp is a leading researcher in the fields of drug delivery, medical devices, stem cell therapeutics, and tissue adhesives. He is an Associate Professor at Brigham and Women’s Hospital, Harvard Medical School, Principal Faculty at the Harvard Stem Cell Institute, and an affiliate faculty at the Broad Institute and at the Harvard-MIT Division of Health Sciences and Technology (where he teaches to MIT-Sloan business school students). He has published >100 peer-reviewed papers (with >12,250 citations) and has given 250 national and international invited lectures and has 65 issued or pending patents. Several technologies developed in his lab have formed the foundation for multiple products on the market and currently under development and for the launch of four companies including Skintifique, Gecko Biomedical, Alivio Therapeutics, Frequency Therapeutics. Karp’s co-founded companies collectively employ >60 people.

His laboratory has been funded by multiple companies, foundations and governmental funding agencies including the Bill and Melinda Gates Foundation, NFL, Johnson & Johnson, Phillips, Sanofi, UCB, NIH, DOD, US Army, Kenneth Rainin Foundation, Helmsley Trust, JDRF, Rheumatology Research Foundation, Coulter Foundation, Prostate Cancer Foundation, Brain Science Foundation, American Heart Association, Deshpande Foundation, Institute for Pediatric Innovation, Boston Children’s Hospital, Brigham and Women’s Hospital, the Government of India and the Government of Korea. Dr. Karp also won an internal Shark Tank award judged by Kevin O’Leary.


28 Biographies

Karp’s work has been discussed in hundreds of newspapers, online websites, television newscasts, and radio shows around the world including CNN, ABC News, NBC, Boston Globe, LA Times, BBC, Discovery, National Geographic, The Atlantic, The Guardian, American Museum for Natural History, Popular Mechanics, CTV Canada AM. Karp has also appeared multiple times on CBC’s Quirks and Quarks and NPR Science Fridays.

His work has been selected by Popular Mechanic’s “Top 20 New Biotech Breakthroughs that Will Change Medicine.” He gave a TEDMED talk at the Kennedy Center in DC on bioinspired medical innovation and since 2015 has been a member of the TEDMED Editorial Advisory Board (only member to be elected to the board 3 years in a row). In 2015 and 2016 he received Breakthrough Awards from the Kenneth Rainin Foundation and in 2015 was a commencement speaker in at the University of Toronto. He also serves as a consultant to the Kenneth Rainin Foundation and the Crohn’s and Colitis Foundation on the topic of new technologies for Inflammatory Bowel Disease.

Long Phi LeDirector of Technology Development, Center for Integrated Diagnostics, MGH

Dr. Le is a practicing molecular pathologist who is currently the Director of Technology Development at the MGH Center for Integrated Diagnostics. His clinical and research interests include development of novel target enrichment, bioinformatics analysis, and medical informatics solutions for next-generation sequencing and their application for clinical molecular diagnostics. He has a strong interest in applying big data descrip-tive and predictive analytics in healthcare with the goal of effectively and efficiently delivering laboratory results and clinical decision support.

Danny LevnerCTO, Emulate

Daniel Levner is Emulate’s Chief Technology Officer. Prior to joining Emulate’s founding team, he was a Se-nior Staff Scientist with the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he led the advanced engineering team responsible for developing Emulate’s Organs-on-Chips platform. Levner played a key leadership role in managing the multidisciplinary Organs-on-Chips team by formulat-ing innovative approaches for fostering close collaboration and in-depth exchange between biologists and engineers. Levner brings this tight integration of disciplines to Emulate, where it is a defining part of the company’s culture.

Prior to directing the Organs-on-Chips program, Levner worked with world-renowned Harvard geneticist Prof. George M. Church in programs related to medical diagnostics, DNA/RNA sequencing tools, and multiplexed analysis techniques. As an entrepreneur, Levner co-founded a medical diagnostics startup company, and earlier in his career, an optical telecommunications startup company. Levner received his Ph.D. in electrical engineering from Stanford University as well as an M.S. in aeronautics and astronautics, also from Stanford. He has authored numerous publications and more than 20 issued and pending patents.


Biographies 29

Steve London Partner, Pepper Hamilton

Steve London joined Pepper Hamilton as a partner 10 years ago to open Pepper Hamilton’s Boston office. He is a member of the firm’s Health Sciences Department. For more than 25 years, he has been repre-senting entrepreneurial life sciences companies developing and commercializing medical devices, biotech, drugs and pharma, technologies servicing the life sciences and health care industries, as well as the sourc-es of capital that finance these companies. He guides these enterprises throughout the entire corporate life cycle. He leads angel, venture capital and private equity financings, IPOs, mergers and acquisitions, strategic relationships, and licensing and commercial transactions. He serves as general corporate coun-sel to private and publicly-traded life sciences companies, working closely with senior management and boards of directors in corporate governance matters, building teams, accessing capital, enhancing asset portfolios, and regulatory compliance. He also has extensive experience in representing companies from throughout the world in entering the US market and engaging in cross border transactions.

Steve is listed in The Best Lawyers in America and 2017 New England Best Lawyers. He is a frequent speaker on a variety of topics relating to the growth and development of entrepreneurial ventures.

Steve is a graduate of Brandeis University and Georgetown University Law Center.

Kathryn (Katy) McCabeDirector of Business Development- Emerging Technology and Innovation, Eli Lilly

Kathryn (Katy) McCabe is Director of Business Development- Emerging Technology and Innovation for Eli Lilly in Cambridge, MA. Katy directly engages with the Cambridge innovation ecosystem with a focus on early discovery to help grow new therapeutics. She works with strategic limited partner Venture Capital firms to recommend and vet new companies, searches and evaluates in-licensing opportunities, connects directly companies in incubators such as Lab Central, and scouts new collaborations for Lilly R&D.

Prior to joining Lilly, Katy led technical and strategic assessments for partnerships, acquisitions, and com-pany strategy across Gene Therapy, Immunology, Oncology, and Hematology at Baxalta. At GlaxoSmith-Kline, Katy directed 3 high profile academic/industry collaborations at the Harvard Stem Cell Institute in neurodegeneration (now in PhII clinical trial), retinal disease, and muscle regeneration. At Advanced Cell Technology (now Astellas), Katy was the Director of Preclinical Ocular Program where she managed a small team of senior scientists to generate stem cell derived products for the treatment of ocular diseases.

Travis A. McCreadyPresident & CEO, Massachusetts Life Sciences Center

Travis McCready is the President and CEO of the Massachusetts Life Sciences Center, a $1 billion pub-lic–private partnership with the mission of advancing the life sciences sector in Massachusetts. He directs and oversees the center’s investment strategy, along with the agency’s operations, programs, and partner-ships. Previously, Mr. McCready served as the Vice President for Programs at The Boston Foundation, directing the Foundation’s grants and community investment strategy to benefit the people of Greater Boston. Prior to that, he was the first Executive Director of the Kendall Square Association, responsible for


30 Biographies

growing the innovation economy of Kendall Square, one of the Commonwealth’s most economically robust districts. He has also held the Chief Operating Officer and CFO positions at the Massachusetts Convention Center Authority, overseeing the operations and finances for the three convention centers in Massachusetts.

Mr. McCready serves on the Boards of the American Repertory Theater in Cambridge, Beth Israel Deacon-ess Medical Center, the Conservation Law Foundation, Life Science Cares, and WBUR. He has served on the Economic Development Planning Council under two governors, including co-chairing the subcommittee on innovation and entrepreneurship. In 2009, he was named one of Boston’s top “40 under 40” young busi-ness leaders by the Boston Business Journal. Mr. McCready is a frequent speaker on economic develop-ment strategy as it relates to the convergence of private, public, and not-for-profit interests, and his blog, Life Sciences Discourses, has been recognized by The Boston Globe.

Mr. McCready received his B.A. from Yale University and J.D. from the University of Iowa, and began his law career as a corporate attorney in Minneapolis, MN.

Glenn A. MillerMarket Sector Leader, Partners Healthcare Innovation

Dr. Miller is a Market Sector Leader at Partners Healthcare Innovation. Before joining Partners Healthcare, Dr. Miller was President of CDx Vision, a consultancy specializing in Precision Medicine and Companion Diagnostics. Dr. Miller has nearly 30 years of experience in the clinical laboratory industry and personalized medicine including serving as Executive Vice President and Chief Technology Officer of MolecularMD; Vice President and Head of Personalized Healthcare and Biomarker Strategy, Portfolio and Alliances for Astra-Zeneca Pharmaceuticals; and leading Genzyme Analytical Services as Vice President and General Manager while directing the Research and Development efforts of Genzyme Genetics. Dr. Miller also serves as Chair of the Scientific Advisory Board and is a member of the Board of Directors of Biomarker Strategies. He re-ceived his Ph.D. in Experimental Pathology from Roswell Park Memorial Institute, a graduate division of the State University of New York at Buffalo. He completed his postdoctoral work in molecular hematology and viral leukemogenesis at Memorial Sloan Kettering Cancer Center and molecular genetics at the University of Miami School of Medicine.

Walter OgierCo-founder, Acetylon

Mr. Ogier has 30 years of life science industry managerial experience developing and commercializing small molecule drugs, stem and immune cell therapies, monoclonal antibody and gene therapies, and medical devices for the treatment of cancers and inflammatory, genetic, neurologic, hepatic, and car-diovascular dis-eases. Over the past 20 years as CEO, he has raised a total of $250M in operating capital for development stage life science companies. And he has provided multi-fold returns for investors, most recently in 2016 from the sale of Acetylon Pharmaceuticals to Celgene pursuant to a $2B option and corporate partnership that non-dilutively funded Acetylon’s successful Phase 1 & 2 clinical devel-opment program in multiple my-eloma, and in 2001 via the sale of stem cell therapy pioneer Eligix Inc. to BioTransplant. He also from 2001 to 2005 established the Lentiglobin® stem cell gene therapy prod-uct and clinical development programs at Genetix Pharmaceuticals that have resulted in the perma-nent correction of beta-thalassemia (a severe, life shortening, pediatric, genetic blood disease that afflicts millions of individuals worldwide) leading to the highly successful IPO of (rebranded) Bluebird Bio in 2013.


Biographies 31

Mr. Ogier currently serves as President & CEO of privately held, Boston Seaport-based Regenacy Pharma-ceuticals, which was spun out from Acetylon prior to the Celgene acquisition. Regenacy is de-veloping se-lective histone deacetylase (HDAC) inhibitors including the Phase 2 drug candidate rico-linostat for diabetic neuropathic pain, as well as pipeline programs for sickle cell disease and other criti-cal human diseases. He also serves as a director of Biothera Pharmaceuticals (Egan, MN), Thetis Phar-maceuticals (Branford, CT), and Longevity Therapeutics (Chicago, IL) and Chairman of Katahdin Phar-maceuticals (Portland, ME) and serves as Class Agent for the Williams College Alumni Fund. Mr. Ogier received a BA magna cum laude in chemistry from Williams and an MBA from the Yale School of Man-agement.

Swati PrasadSenior Manager of Business Development and Scientific Alliances, Charles River Laboratories.

Dr. Swati Prasad, MBA is Senior Manager of Business Development and Scientific Alliances at Charles River Laboratories. Swati manages drug discovery alliances and strategic partnerships with focus on creative busi-ness models to increase revenues, penetrate markets and strengthen drug discovery portfolio. Previously, she was at AstraZeneca Pharmaceuticals where she managed external collaborations and partnerships. She has extensive experience in large pharma, CRO and life science industry with hands-on drug develop-ment experience across diverse therapeutic areas and entire lifecycle, from preclinical research to clinical development candidates. She holds a doctorate degree in Chemistry from Tata Institute of Fundamental Re-search, India, an MBA from Wilmington University and a bachelors in Classical Music from Prayag Sangeet Samiti, India.

Jen RiceAssociate Director of Business Development, OTD, Harvard University

Jen Rice, Ph.D. is an Associate Director of Business Development at Harvard University’s Office of Technol-ogy Development (OTD). As an Associate Director, Jen supports commercialization activities for Harvard Medical School and Harvard T.H. Chan School of Public Health by working with researchers to patent, market, and license their inventions, as well as identify industry-sponsored research opportunities. Prior to joining Harvard, Jen was a Technology Manager and Special Programs Manager in the Office of Technology Management (OTM) at the University of Illinois at Urbana-Champaign. Jen holds a B.A. in Biochemistry and Molecular Biology from Boston University, and a Ph.D. in Microbiology from the University of Illinois at Urbana-Champaign.

Kevin J. SlatkavitzPresident & Founder, ThinkQuality, LLC

Kevin is President and Founder of ThinkQuality, LLC – a strategic consulting firm aimed at working with start-ups and large multinationals across the Pharma/BioPharma ecosystem to rethink their specific challenges, opportunities and business case for Quality. Understanding and leveraging the return on Quality investment is one of the most underutilized means for demonstrating and communicating value to investors, regulators,


32 Biographies

patients and other key stakeholders throughout a company’s project lifecycle. ThinkQuality, LLC offers practi-cal, fit-for-purpose strategies and coaching to do this proactively, collaboratively and more predictably.

Through ThinkQuality, LLC, Kevin applies his extensive insights into the complex and global challenges and opportunities of small and large organizations from early stage discovery/development through drug product approval/launch and beyond – drawing on experience from numerous developed/approved novel products including LIPITORâ and LINZESSâ. He leverages proactive strategies and solutions, including early and ongoing engagement with the FDA, for enabling innovation and speed to market - creating a competitive advantage while building mutual trust and respect with stakeholders.

Kevin has a successful track record of regulatory approvals and inspections – building relationships and gaining organizational alignment along the way. He is a champion of collaborative problem solving and sci-ence-based risk management, strategic leadership and organizational design and development. In addition, he understands the different language of executives and scientists and can bring organizations together with a common understanding of “return on Quality investment”.

He earned a B.S. in Chemistry at Tufts University and a Ph.D. in Analytical Chemistry from the University of Massachusetts at Amherst – beginning his career as a scientist/analytical chemist in the consumer products industry. Kevin transitioned into a broader Quality role while at Warner-Lambert/Parke Davis (now Pfizer). Since then, he has served in senior, global Quality leadership roles at Purdue Pharma (Director, Research Quality Assurance), AstraZeneca (Global Head, R&D GMP Quality Assurance), Nektar Therapeutics (Vice President and Head, Quality) and Ironwood Pharmaceuticals (Vice President and Head, Global Quality).

Greg L. VerdineErving Professor of Chemistry, Harvard University and Harvard Medical School

Gregory Verdine is a pioneer in the field of chemical biology, a serial biotech entrepreneur and a life science venture capitalist. In an independent academic career at Harvard University and Harvard Medical School spanning nearly 3 decades, he has elucidated the molecular mechanism of epigenetic DNA methylation and the pathways by which certain genotoxic forms of DNA damage are surveilled in and eradicated from the genome. He is a leading figure in the field of new therapeutic modalities, and has developed a new class of therapeutics termed stapled peptides, which are currently in clinical development and have received much attention for their ability to drug targets previously considered “undruggable”. Dr. Verdine is Erving Professor of Chemistry in the Departments of Stem Cell and Regenerative Biology, Chemistry and Chemical Biology, and Molecular and Cellular Biology.

Dr. Verdine has made important contributions in the translation of bench science to the bedside. He has founded or co-founded a number of successful biotechnology companies, including Enanta Pharmaceuticals (Nasdaq ENTA), Gloucester Pharmaceuticals (acquired by Celgene), Tokai Pharmaceuticals (Nasdaq TKAI), WaVe Life Sciences (Nasdaq WVE), Eleven Biotherapeutics (Nasdaq EBIO), Warp Drive Bio, Aileron Thera-peutics, and FogPharma. To date, these companies have succeeded in gaining FDA approval for two drugs, romidepsin (Gloucester/Celgene) and paritaprevir (Enanta/AbbVie). He has also worked in the venture capi-tal industry as a Venture Partner with Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ven-tures, and as a Special Advisor to Texas Pacific Group. He co-founded and served as the founding President of the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy, for which he continues to serve as Director.

Dr. Verdine is Chairman of the Board of Directors of WaVe Life Sciences, and is a Director of Warp Drive Bio, for which he also Chairs the company’s Scientific Advisory Board. He is currently President and CEO of FogPharma, a biotechnology company focused on a transformative drug discovery platform based on Cell-Penetrating Miniproteins as well as LifeMine, the first biotechnology company exploiting the unique ability of


Biographies 33

fungi to produce powerful drugs optimized through billions of years of evolution, and deploying these mol-ecules for the treatment of intractable human diseases via novel biological mechanisms. Dr. Verdine serves on the Board of Scientific Consultants of the Memorial Sloan-Kettering Research Institute and on the Board of Scientific Advisors of the National Cancer Institute.

Dr. Verdine holds a PhD in chemistry from Columbia University, a B.S. in chemistry from St. Joseph’s Univer-sity, and served as an NIH postdoctoral fellow in molecular biology at MIT and Harvard Medical School. He has won numerous prestigious awards, including most recently the AACR Award for Excellence in Chemistry in Cancer Research, and the Nobel Laureate Signature Award.

Rich Wilmot Head, Philips Ventures

Rich is the head of Philips Ventures. Prior to his current role, Rich launched and led a healthcare market dili-gence team responsible for market opportunity assessment on a global basis across all Philips businesses. Rich joined Philips from Partners HealthCare, where he was a principal for the Partners Innovation Fund (PIF), and oversaw the creation, launching and funding of new ventures generated from Partners innova-tive research discoveries. He also spent time in the investment banking industry, working for both Bank of America as well as Deutsche Bank Securities. Rich holds degree from Harvard University in engineering sciences and was an adjunct professor at Tufts University for several years where he taught a course on Entrepreneurial Finance.


34 Biographies


Planning Committee 35

MALSI Day Planning Committee

Chair

Abi Barrow, Massachusetts Technology Transfer Center

Content

Richard Anders, MA Medical AngelsAnu Ahuja, Brandeis University

Abi Barrow, Massachusetts Technology Transfer Center Carl Berke, Partners Healthcare

Roger Frechette, New England PharmAssociates Nina Green, Consultant

Imran Nasrullah, Boehringer IngelheimKevin O’Sullivan, Massachusetts Biomedical Initiatives

Avi Spier, Novartis

Marketplace

Shelley Amster, ShelleyCO, LLC

Research & Startup Showcase and Logistics

Tatiana Demidova, Harvard University Rebecca Gibbs, Harvard Biotech Club

Julia Goldberg, Massachusetts Technology Transfer Center

Reception

Denise Aronson, Safety Partners, Inc. Lauren Laidlaw, Safety Partners, Inc.

Team

Nazita Gamini, Brandeis UniversityAlan Lucas, Consultant


36 Planning Committee


37

Poster Presenters

Arex Life Sciences LLC Presented by: Barb Cohen, Co-Founder & CSO [email protected] Poster Title: Increasing Pregnancy Achievement in Intrauterine Insemination with an As-say that Identifies Entry of Sperm into an Immune Silencing State

Boston Children’s Hospital, Beth Israel Deaconess Medical Center, Harvard Medical School

Presented by: Michela [email protected] Poster Title: Novel Benzimidazole Compound for the Treatment of Metastatic Cancer

Brigham and Women’s HospitalPresented by: Peng Li, Postdoctoral [email protected] Poster Title: Physiological Consequences of Altered Fractal Regulation: Application in De-mentia

Brownmed, Inc & Brigham and Women’s HospitalPresented by: Anna Mei, Research [email protected] Poster Title: Efficacy of Vibrating Gloves and a Smartphone Pain App to Help Manage Chronic Pain


38 Poster Presenters

CellanyxPresented by:Ashok Chander, [email protected] Title:Dynamic Live-Cell Phenotypic Biomarker Platform for Cancer Risk Determination, Biomarker Validation, Accelerated Therapeutic Development

ClockCoach, Inc

Presented by: Alexander Stankiewicz, Director of Business [email protected] Poster Title: Fighting Insomnia and Circadian Misalignment through Deep-Learning

Danio Lab Presented by: Rory Francis, Founder and [email protected] Title:Accelerating research through standardization of animal husbandry

Dermalytica Inc. Presented by:James Wang, [email protected] Title:First-in-class selective antimicrobial treatment for acne vulgaris

ElektrofiPresented by: Daniel Dadon, Director, Scientific [email protected] Poster Title: High-concentration, Low-viscosity Formulation of Biologics.


39

Fairbanks Pharmaceuticals Inc Presented by: Alan Schneyer, CEO/[email protected] Poster Title:New Diabetes Therapy To Restore Beta Cell Function And Number

Harvard Medical SchoolPresented by:

Parastoo Khoshakhlagh, Postdoctoral Research [email protected] Title: Transcription factor-mediated cell engineering for stem cell therapy applica-tions

Harvard Medical SchoolPresented by: Mahmoud Nasr, Postdoctoral Research [email protected] Poster Title: Covalently Circularized Nanodiscs: Novel platforms to accelerate membrane protein studies and drug discovery

Harvard Medical School Presented by: Gleb Kuznetsov, PhD [email protected] Poster Title: Engineering Proteins with Deep Learning and High-throughput Synthesis

Harvard T.H. Chan School of Public HealthPresented by: Quan Lu, Associate [email protected] Poster Title: ARMMs as a versatile platform for intracellular delivery of macromolecules


40 Poster Presenters

HydroGlyde Presented by: Stacy Chin, Co-founder & CEO [email protected] Poster Title: Hydrophilic Latex Condom Coating to Promote Correct & Consistent Usage

InVitroMetrixPresented by: Maryanwal Abdou, Research Intern [email protected] Poster Title: InVitro-Q: A high-throughput biosensor used to evaluate the mechanism of phagocytosis of macrophages using different particles

InVitroMetrixPresented by:Monica Tawadros, Thesis [email protected] Poster Title: Companion Diagnostics for Breast Cancer Chemotherapeutics

IOMICS CorporationPresented by: Joseph Gormley, [email protected] Poster Title: Automating Deep Phenotype Discovery

nanoView Diagnostics Inc.Presented by: David Freedman , CEO [email protected] Title: Digital Detection of Single Exosomes for Characterization and Diagnostics


41

Northeastern UniversityPresented by: Stella Banou, PhD [email protected] Poster Title: Body-Generated Password Authentication System using Galvanic Coupling

Northeastern UniversityPresented by: Aida López, Master [email protected] Title: Silver Palladium and Silver Platinum Nanoparticles as New Antimicrobial Agents

Prospective Research, Inc.Presented by: Dakota Hamill, [email protected] Poster Title: Bacterial Communication Chemicals Drive Production of Novel Bioactive Molecules from Actinomycetes

Trek Therapeutics, PBC Presented by:Ann Kwong, CEO, President & Co-founder [email protected] Poster Title: Why Highly Effective Drugs Are Not Enough: An Affordable Solution to Erad-icating HCV

Tufts UniversityPresented by: Weibo Zhang, Research [email protected] Poster Title: Decellularized Tooth Bud ECM Scaffolds for Tooth Regeneration


42

Tufts UniversityPresented by: Elizabeth Smith, PhD [email protected] Poster Title: The Whole Tooth and Nothing but the Tooth: Bioengineered GelMA Tooth Bud Constructs for Future Applications in Implant Dentistry

UrSure Inc.Presented by: Giffin Daughtridge,MPA [email protected] Title: Diagnostics to Drive HIV Prevention

Wyss Institute for Biologically Inspired Engineering at Harvard University

Presented by: Mark Cartwright , Staff [email protected] Poster Title: Biomaterial-Based Broad Spectrum Infection Vaccine


Presented by: Robert Cunningham, Technology Transfer [email protected] Poster Title: Title RAPID Pathogen Capture System


43


Presented by: Sasha Stafford, Staff Scientist [email protected] Poster Title: Biodegradable Click Alginates Hydrogels for Drug Delivery Applications


44 Innovator's Marketplace Exhibitors

Innovators’ Marketplace ExhibitorsLife Science Products and Services Aragen Bioscience, Inc. ..............................................................................www.aragenbio.com

Cambridge Biolabs ..............................................................................................www.biolabs.io

Core Facilities, UMass IALS .................................................www.umass.edu/ials/core-facilities

Crows Nest Bio, LLC .............................................................................www.crowsnestbio.com

Envigo ............................................................................................................. www.envigo.com

Fikst Product Development ..................................................................................www.fikst.com

Fisher Scientific ...................................................................................... www.thermofisher.com

Framingham State University ...................................................................www.framingham.edu

ITR Laboratories ........................................................................................ http://www.itrlab.com

Juniper Pharma Services ...........................................................http://www.juniperpharma.com

Kalexsyn, Inc. ...............................................................................................www.kalexsyn.com

Labmate ............................................................................................................ www.labmate.us

LaunchWorks Manufacturing Lab ....................................................... www.launchworksml.com

Mass Innovation Labs ................................................................. www.massinnovationlabs.com

MedChem Partners .......................................................................www.medchempartners.com

Mispro Biotech Services .......................................................................www.misprobiotech.com

NorthEast Preclinical Network ............................................................................www.NEPN.net

Organix Inc. ................................................................................................www.organixinc.com

Proteros .........................................................................................................www.proteros.com

Safety Partners, Inc ........................................................................www.safetypartnersinc.com

SEQLL .................................................................................................................www.seqll.com

Toxikon ............................................................................................................www.toxikon.com

Entrepreneurship SupportMassachusetts Life Sciences Center ..............................................www.masslifesciences.com

Massachusetts Technology Trasfer Center .................................................www.mattcenter.org

MassBio .......................................................................................................... www.massbio.org

MALSI ............................................................................ www.linkedin.com/groups?gid=113959

Boston Life Science Networking ..................................................... www.bostonlifescience.com


Innovator's Marketplace Exhibitors 45

CreaGen Life Science Incubator .............................................................. www.creagenbio.com

Harvard Alumni Entrepreneurs ....................................... www.harvardalumnientrepreneurs.org

Harvard Biotechnology Club ................................................................. www.thebiotechclub.org

Life Science Nation ......................................................................... www.lifesciencenation.com

Mansfield Bio-Incubator ..................................................................................... www.bioinc.org

Massachusetts Medical Device Development Center (M2D2) ....................www.uml.edu/m2d2

MASS-AWIS ................................................................................................www.mass-awis.org

Massachusetts Biomedical Initiatives ...................................................... www.massbiomed.org

MassMedic ...............................................................................................www.massmedic.com

Massachusetts Technology Leadership Council ............................... www.masstechleaders.org

Massachusetts Technology Collaborative .................................................... www.masstech.org

MassGlobal Partners ...................................................................www.massglobalpartners.com

MVVF ....................................................................................................................www.mvvf.org

North Shore InnoVentures ..................................................................................... www.nsiv.org

OPEN ............................................................................................ www.open-newengland.com

TiE ................................................................................................................www.tie-boston.org

VentureWell ..............................................................................................www.cventurewell.org

WEST ..............................................................................................................www.westorg.org

Funding

CIMIT .................................................................................................................... www.cimit.org

Mass Medical Angels ........................................................................www.massmedangels.com

MassChallenge Inc. ..............................................................................www.masschallenge.org

New England Venture Capital Association ............................................www.newenglandvc.org

The Capital Network – TCN ..............................................................www.thecapitalnetwork.org

Professional Services

Burns & Levinson LLP ...................................................................................www.burnslev.com

Lathrop &Gage LLP ................................................................................www.lathropgage.com

PCI Synthesis ......................................................................................... www.pcisynthesis.com

Pepper Hamilton LLP ................................................................................www.pepperlaw.com


46 Innovator's Marketplace Exhibitors

Notes

dr. abigail a. barrow chair malsi · 2017-06-05 · joe gormley, cto, iomics corp ali...

Documents